Abstract The canonical transient receptor potential (TRPC) proteins have been recognized as key players in calcium entry pathways activated through phospholipase-C-coupled receptors. While it is clearly demonstrated that members of the TRPC3/6/7 subfamily are activated by diacylglycerol, the mechanism by which phospholipase C activates members of the TRPC1/4/5 subfamily remains a mystery. In this paper, we provide evidence for both negative and positive modulatory roles for membrane polyphosphoinositides in the regulation of TRPC5 channels. Depletion of polyphosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate (PIP 2 ) through inhibition of phosphatidylinositol 4-kinase activates calcium entry and membrane currents in TRPC5-expressing but not in TRPC3-or TRPC7-expressing cells. Inclusion of polyphosphatidylinositol 4-phosphate or PIP 2 , but not phosphatidylinositol 3,4,5-trisphosphate, in the patch pipette inhibited TRPC5 currents. Paradoxically, depletion of PIP 2 with a directed 5-phosphatase strategy inhibited TRPC5. Furthermore, when the activity of single TRPC5 channels was examined in excised patches, the channels were robustly activated by PIP 2 . These findings indicate complex functions for regulation of TRPC5 by PIP 2 , and we propose that membrane polyphosphoinositides may have at least two distinct functions in regulating TRPC5 channel activity.
Introduction
Calcium signaling in many cell types is initiated by stimulation of membrane receptors coupled to polyphosphoinositide-specific phospholipase C (PLC). The action of PLC on the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP 2 ) leads to the formation of two second messengers: inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG). IP 3 activates IP 3 receptor channels in the endoplasmic reticulum and causes release of intracellular stored Ca 2+ [1] . The fall in Ca 2+ content within the lumen of the endoplasmic reticulum then signals the subsequent activation of plasma membrane calcium-permeable channels, a process known as capacitative Ca 2+ entry (CCE) or store-operated Ca 2+ entry [2] [3] [4] . Although CCE seems to be present ubiquitously in receptor-regulated non-excitable cells, a wide variety of Ca 2+ -permeable channels are activated downstream of the PLC pathway by mechanisms not directly related to store depletion. Examples include channels activated by mechanisms involving IP 3 , cytosolic Ca 2+ , DAG, cyclic nucleotides, phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ), and arachidonic acid (for review, see [5, 6] ). During the last decade, several investigations have implicated the members of the transient receptor potential (TRP) family of channel proteins as candidates for some of these Ca 2+ entry pathways [6] [7] [8] [9] [10] [11] . TRP proteins constitute a large superfamily of ion channels that are expressed in many tissues and cell types [12] . TRP channels are activated by a wide variety of external stimuli ranging from temperature and oxidative stress to hormones, growth factors, and neurotransmitters [10, 7, 13] . TRP channels are cation-permeable channels and are now fully recognized as key players in the maintenance of ion homeostasis and in cell signaling pathways. The TRP superfamily can be divided into three major families: (1) channels homologous to the vanilloid receptor called TRPV which are activated by a variety of signals, including vanilloid compounds such as capsaicin, noxious signals, hypotonic cell swelling and heat; TRPV family consists of six Ca 2+ -permeable channels [14, 7, [15] [16] [17] ; (2) the Melastatin-related TRP channel family (TRPM) containing eight members with diverse functional properties such as mediating Ca 2+ influx, controlling Mg 2+ entry, modulating the membrane potential, and sensing cold and menthol in sensory neurons [18] [19] [20] 13] ; (3) the canonical TRP family (TRPC), named for being structurally the closest to the superfamily founder, Drosophila TRP, are all activated through PLC-coupled receptors and were therefore proposed to encode components of native PLCcoupled channels, such as store-operated channels and second-messenger-operated channels [8, 21, 11] .
The TRPC family contains seven members (TRPC1 through 7). TRPC2 is a pseudogene in humans and is involved in pheromone sensing in other mammals [22] . TRPC3/6/7 represents a subfamily within TRPC family whose members can be activated by diacylglycerol produced by PLC action on PIP 2 [23] [24] [25] [26] [27] . However, the mechanism of activation via PLC-coupled receptors of members of the TRPC1/4/5 subfamily is still unclear. These channels are believed to play important roles in diverse physiological functions, for example in regulation of vascular tone [28] and in neurite outgrowth [29] . While most investigators agree that PLC is necessary for receptor activation of this group, the general finding is that neither IP 3 nor DAG activates these channels [27, 30] . Otsuguro et al. [31] suggested that breakdown of PIP 2 , in conjunction with inputs from G-proteins and [Ca 2+ ] i , leads to activation of TRPC4. In the current study, we have investigated the role of inositol lipids in regulation and activation of TRPC5. Consistent with the findings of Otsuguro et al. for TRPC4, we show that in intact cells, pharmacological depletion of phosphatidylinositol 4-phosphate (PIP) and PIP 2 specifically activates TRPC5 channels, while inclusion of these polyphosphoinositides in the patch pipette inhibits TRPC5 currents. However, depletion of PIP 2 by a targeted 5-phosphatase inhibited TRPC5 activity, and in excised patches, PIP 2 activated TRPC5 channels. These data suggest that PIP and/or PIP 2 exert multiple effects on TRPC5.
Materials and methods

Reagents
Methacholine, wortmannin, LY294002, and rapamycin were purchased from Calbiochem. D(+)-sn-1,2-di-O-octanoylglyceryl,3-O-phospholinked (DiC8) polyphosphoinositides, PIP, PIP 2 , and PIP 3 were purchased from Echelon Biosciences Incorporated.
Cell culture and cell lines
Human embryonic kidney (HEK293) cells were obtained from ATCC and were transfected using Lipofectamine 2000 reagent (Invitrogen) according to the vendor's instructions, with pcDNA3 vector containing the coding sequence of TRPC3 or TRPC5. Cells stably expressing hTRPC3-green fluorescent protein (TRPC3-GFP) fusion protein used in this study were described earlier [26, 32, 33] . Cells stably expressing TRPC5 [murine TRPC5 complementary DNA (cDNA) was generously donated by Dr. Lutz Birnbaumer, National Institute of Environmental Health Sciences] were generated after transfection and subsequent selection by antibiotic resistance. Several clones were selected that gave robust Ca 2+ entry signals in response to methacholine (for example, Fig. 1a ). Both TRPC3-GFP-and TRPC5-expressing cell lines were grown under selection with G418 at 37°C in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum and 2 mM glutamine in a humidified 95% air, 5% CO 2 incubator.
Ca
2+ measurements Ca 2+ measurements were carried out with either Fura-2-AM or Fluo-4-AM and a cell imaging system (Intracellular Imaging, Cincinnati, OH, USA) as described previously [34] . For Fura-2 measurements, the ratio obtained by dividing the emitted fluorescence from excitation at 340 nm by the emitted fluorescence measured after excitation at 380 nm is reported as in indicator of changes in intracellular Ca 2+ concentration. For experiments using wortmannin, which is UV-sensitive, Ca 2+ measurements were carried out with the visible wavelength dye, Fluo-4. Briefly, cells were loaded with either 1 μM of Fura-2/AM (for 30 min) or 4 μM of Fluo-4/AM (for 1 h), then washed and bathed in HEPES-buffered saline solution (in mM, 140 NaCl, 4.7 KCl, 10 CsCl, 2 CaCl 2 , 1.13 MgCl 2 , 10 glucose, and 10 HEPES, pH 7.4) for at least 10 min before Ca 2+ measurements are made. Basal cytosolic Ca 2+ was determined in a field containing up to 100 cells, and cytosolic Ca 2+ was monitored after addition of enzyme inhibitors and/or receptor agonists.
Electrophysiology
Ion currents were recorded by using either the whole-cell or nystatin-patch configuration using an Axopatch-200B amplifier (Axon Instruments, USA) as described previously [26] . The patch pipettes were pulled with a pipette puller (Sutter) from glass capillaries (Corning glass, 7052) and fire-polished. The finished pipettes had resistances ranging between 2 and 5 MΩ when filled with the following solution (for whole-cell experiments, in mM): 140 CsCl, 10 BAPTA (cesium salt), 1 MgCl 2 , 2.2 CaCl 2 , and 10 HEPES, pH 7.2, with Tris base. In most experiments, this pipette solution was buffered to~100 nM free Ca 2+ calculated using WinmaxC software available from Stanford University website. For nystatin-patch experiments, the pipette contained (in mM): CsCl, 55; Cs 2 SO 4 , 70; MgCl 2 , 1; CaCl 2 , 1; glucose, 5; HEPES, 10; nystatin concentration, 200 μg/ml. The bath solution was (in mM): 140 NaCl, 4.7 KCl, 10 CsCl, 2.0 MgCl 2 , 10 glucose, 2.0 or 10 CaCl 2 , and 10 HEPES, pH 7.4, with NaOH. The osmolarity of these solutions was adjusted to 290-310 mOsm with glucose. Bath solution change was accomplished by gentle perfusion. Wild-type HEK cells (HEK-Wt), TRPC3-GFP-, and TRPC5-expressing HEK293 cells were plated the day before on coverslips. Before starting the experiments, coverslips were mounted in a perfusion chamber and electrophysiological measurements were performed at room temperature. An agar bridge served as the electrical connection between the bath and the signal ground. Whole cell currents were elicited by voltage stimuli lasting 250 ms, delivered every 5 s, with voltage ramps from -100 to +100 mV. Data were sampled at 5 kHz, filtered at 1 kHz, acquired with pCLAMP 9.0 software, and analyzed with CLAMPFIT 9.0 (Axon).
For the single-channel measurements in the inside-out configuration, the composition of the solutions present in a b c Depletion of PIP 2 levels using rapamycin PIP 2 depletion was achieved by targeting of the type IV phosphatidylinositol 5-phosphatase (PI5-phosphatase) to the plasma membrane [35] . HEK293 Cells expressing TRPC5 were transfected with either a construct (2.5 μg) encoding a membrane-targeted FRB domain of mTOR tagged with monomeric red fluorescent protein (mRFP), or with a construct (2.5 μg) encoding a modified cytoplasmic type IV 5-phosphatase fused to FKBP12 and tagged with mRFP, or co-transfected with both constructs. The plasma membrane-targeted FRB domain of mTOR can be heterodimerized with FKBP12-5-phosphatase using rapamycin (100 nM) as described previously [35] .
Results
Activation of TRPC5 by PLC-coupled receptors
An HEK293 cell line stably expressing TRPC5 channels (described in "Materials and methods") was used throughout this study. After activation with the muscarinic agonist, methacholine, TRPC5-expressing cells exhibited a Ca 2+ entry pathway that was not found in the wild-type cells. As described earlier, when used at concentrations ranging between 1 and 5 μM, gadolinium (Gd 3+ ) is a potent inhibitor of CCE in HEK293 cells [32, 36] . As expected, methacholine-activated CCE in HEK-Wt was completely blocked by 5 μM Gd 3+ (Fig. 1a) . As previously shown for TRPC3 [32] and TRPC7 [37] , TRPC5-expressing cells exhibited a receptor-activated Ca 2+ entry pathway that was Gd 3+ -insensitive (Fig. 1a) . However, TRPC5 differs from members of the TRPC3/6/7 subfamily in two significant ways. First, TRPC5 channels were shown previously to be activated by higher concentrations of Gd 3+ (50-100 μM) [38] , while TRPC3 is inhibited by lanthanides at these high concentrations [39] . These results were confirmed in the present study, and we found that TRPC5-expressing HEK cells show a Ca 2+ entry in response to exogenous addition of 50 μM Gd 3+ (Fig. 1b) . Second, the DAG analog, OAG (100 μM) fully activated TRPC3, while it failed to activate TRPC5 channels (Fig. 1c) , in confirmation of the findings of Venkatachalam et al. [27] . Furthermore, application of OAG to TRPC5-expressing HEK293 cells in the presence of the PKC inhibitor GF-109203X (10 μM) also failed to activate TRPC5 channels (data not shown).
PI-4K inhibitors (wortmannin and LY294002) specifically activate TRPC5 but not TRPC3 channels
Since neither second messenger (IP 3 or DAG) produced after PLC breakdown of PIP 2 appears to be involved in the activation of TRPC5 channels ( [27, 40] , this study), we asked whether PIP 2 breakdown itself might be responsible for TRPC5 activation, for example by relieving tonic PIP 2 inhibition of the channels. To test this hypothesis, we first used a pharmacological strategy to deplete polyphosphoinositides in the cells.
The membrane-permeant drugs, wortmannin and LY294002, are known to inhibit the phosphatidylinositol 3-kinase when used at relatively low concentrations (~100 nM and 10 μM, respectively). When used at higher concentrations (20 μM for wortmannin and 100 μM for LY294002), these drugs are known to inhibit the phosphatidylinositol 4-kinase (PI4-K) [41, 42] . PI4-K catalyses the phosphorylation of phosphatidylinositol (PI) into phosphatidylinositol 4-monophosphate (PIP), which in turn is converted into the substrate of PLC, PIP 2 via the action of the enzyme phosphatidylinositol 4-phosphate 5-kinase. Therefore, efficient inhibition of PI4-K leads to subsequent PIP and PIP 2 depletion [41] [42] [43] [44] [45] [46] [47] .
As shown in Fig. 2a , treatment of TRPC5-expressing HEK293 cells with 20 μM wortmannin activates calcium entry in these cells, while no effect of wortmannin was observed in wild-type cells. Similar results were obtained using the drug LY294002 (Fig. 2b) , suggesting that this calcium entry is directly associated with TRPC5 channels and not to non-specific effects of these drugs. Concentrations of these drugs which inhibit phosphoinositide 3-kinase, but not PI4-K (10 μM LY294002, 200 nM wortmannin), did not activate entry (data not shown). When LY294002 was applied to TRPC5-expressing cells in the continuous presence of Ca 2+ , there was a delay of about a minute before Ca 2+ entry ensued (Fig. 3a) , as expected if this drug must penetrate the plasma membrane, inhibit PI4-K, and cause depletion of polyphosphoinositides. Note that LY294002 caused a small release of Ca 2+ (Fig. 2b) that was not seen with wortmannin (Fig. 2a) . However, both drugs induced similar Ca 2+ entry in TRPC5 cells. In addition, we also utilized another structurally dissimilar PI4-K inhibitor, phenylarsine oxide [44, 48] ; this agent caused a large release of Ca 2+ stores and thus was not employed in further experiments. However, we did note that like wortmannin and LY294002, phenylarsine oxide activated Gd 3+ -insensitive Ca 2+ entry in TRPC5-expressing cells and not in wild-type or TRPC3-expressing cells (see below).
The effects of wortmannin and LY294002 are specific to TRPC5 channels. An HEK293 cell line expressing TRPC3 channels showed no increase in calcium entry after application of 100 μM LY294002 (Fig. 2c) . Similar results were obtained with 20 μM wortmannin (data not shown). Rather, receptor activation of TRPC3 channels in HEK293 cells was completely abrogated after treatment with 100 μM LY294002 (Fig. 2d) , presumably because PIP 2 is necessary for TRPC3 activation as a source of DAG, the signal for TRPC3 activation. Similar results were obtained when TRPC3-expressing HEK293 cells were treated with 20 μM wortmannin (data not shown). In addition, TRPC7 behaved identically to TRPC3; Ca 2+ entry was not activated by PI4-K inhibitors, and agonist-activated Ca 2+ entry was blocked by these drugs (data not shown). Note that in Fig. 2d , a smaller but still significant mobilization of Ca 2+ is seen, yet subsequent addition of Ca 2+ shows essentially no TRPC3 activity. This is likely due to the fact that in the presence of PI-4 kinase inhibitors, stimulation of phospholipase-C-linked receptors yields a diminished production of phospholipase C products which is transient due to rapid run down of PIP 2 levels [42, 49] .
The experiments in Fig. 2d 
0001).
Although this is an indirect indicator of PIP 2 , it has the advantage of providing information on PIP 2 specifically available for PLC degradation. This information should be more meaningful than whole-cell levels of polyphosphoinositides which are known to reflect a number of pools of lipids, some not associated with the plasma membrane [50] [51] [52] .
The plasma membrane calcium ATPase is known to be tightly regulated by PIP 2 [53] [54] [55] . Thus, we considered that the rise in Ca 2+ seen in cells treated with inhibitors of PI4-K might result, at least in part, from reduced Ca 2+ extrusion. We examined the rate of Ca 2+ extrusion from TRPC5- while it had no effect on TRPC3-expressing cells (dotted trace). Figure) .
Wortmannin and LY2942002 activate a current in TRPC5-expressing HEK cells similar to that activated by methacholine
We have shown that drugs that deplete polyphosphoinositides such as wortmannin and LY294002 activate a calcium entry pathway in TRPC5-expressing cells but not in TRPC3-or TRPC7-expressing cells or in wild-type HEK293 cells. We next carried out patch-clamp current measurements initially in the perforated patch configuration to determine if these drugs induce an ionic current in TRPC5-expressing HEK293 cells. As shown in Fig. 3 , the muscarinic-cholinergic agonist, carbachol, and both PI4-K inhibitors, activated inward and outward currents in TRPC5-HEK293 cells. None of these agents induced an increased current in non-transfected cells. The currents activated by carbachol and the PI4-K inhibitors were similar in that all three gave activation of larger inward than outward currents, and all three showed the double rectification typical for TRPC channels. In all three cases, current activation appeared transient, while in Ca 2+ experiments, the responses appeared sustained (Figs. 1 and 2) ; the reason for this difference is not known. The only difference between the current responses to carbachol and the inhibitors is that carbachol activated a significantly larger current and acted almost immediately upon addition to the cells, while a variable delay occurred between application of the PI4-K inhibitors and the increase in current. This is consistent with the observations from the Ca 2+ measurements. The mean, background-subtracted inward currents (at −100 mV) were (mean pA/pF±SEM, n): carbachol, −39.6±5.9 (8); LY2942002, −9.3±4.5 (4); wortmannin, −18.5±7.4 (3). The outward currents (at ±100 mV) were (pA/pF, n): carbachol, 21.4±3.8 (8); LY2942002, 6.4±2.4 (4); wortmannin, 13.4±2.2 (3).
While the perforated patch technique permits current measurement under the most physiological condition, i.e., without dialysis of the cytoplasm, the whole-cell mode has the advantage of permitting introduction of reagents, such as enzymes, antibodies, and small molecules. As shown in Fig. 4a , stimulation of TRPC5-expressing HEK293 cells with the muscarinic agonist methacholine activates both small inward (at −100 mV) and larger outward (at +100 mV) currents that were absent in wild-type HEK293 cells (data not shown). The current-voltage (IV) relationship for TRPC5 current depicted in Fig. 4b displayed the characteristic double rectification with strong outward rectification, as previously described for TRPC5 [30, 56] . However, the relative magnitude of the inward current is notably smaller than that seen with perforated patch. We also found that responsiveness to muscarinic agonists appeared to wash out after a period of 5-10 min, after which time, cells seldom responded to receptor activation.
Stimulation of TRPC5-expressing HEK293 cells with 20 μM wortmannin or LY2942002 produced inconsistent results in whole-cell experiments. In some cells, wortmannin induced an increase in both inward and outward currents, although the magnitude of the currents was somewhat smaller than that obtained with methacholine (Fig. 4c) . Wortmannin never induced similar currents in TRPC3-expressing HEK293 cells or HEK293 wild-type cells (data not shown). The IV curve obtained after addition of wortmannin to TRPC5-expressing HEK293 cells (Fig. 4d) was similar to that obtained following TRPC5 activation through muscarinic agonist stimulation. The inconsistency and tendency to washout of the responses in whole-cell configuration were disappointing because this precluded experiments requiring long dialysis times, for example with antibodies directed against PIP 2 .
Wortmannin-activated TRPC5 currents are inhibited by PIP and PIP 2 Our data so far suggest an inhibitory effect of polyphosphoinositides on TRPC5 channels and that this inhibition is relieved by pharmacological procedures that deplete cellular polyphosphoinositides. We then sought to explore the ability of polyphosphoinositides to inhibit wortmannininduced TRPC5 currents in HEK293 cells stably expressing TRPC5 cation channels. Unfortunately, as discussed above, effects of these drugs on membrane currents in the wholecell configuration, which could be used for introduction of phospholipids, were inconsistent. In a series of experiments in which a 30-min pretreatment with wortmannin induced a consistent increase in whole-cell current (an approximate doubling of inward and outward current), cells were then dialyzed with a patch pipette containing either the pipette Fig. 4 The muscarinic agonist methacholine (300 μM) and wortmannin (20 μM) activate an inward and outward current measured by the whole-cell patch-clamp technique in TRPC5-expressing HEK293 cells. a Whole-cell current densities in a TRPC5-expressing cell sampled at +100 and −100 mV. b Current/voltage (I/V) relationship in a TRPC5-expressing cell subjected to 250-ms voltage ramps between −100 and +100 mV before (black trace) and after (gray trace) addition of methacholine. Representative of six independent experiments. c Wortmannin (20 μM) induces an increase in both inward and outward whole-cell currents in TRPC5-expressing cells with no effect on HEK-Wt or TRPC3-expressing HEK293 cells (not shown). The data are averages of the maximum inward and outward currents before and after wortmannin addition from 17 (control) and 15 (wortmannin) experiments. d The IV curve obtained after addition of wortmannin (20 μM) to TRPC5-expressing cells is similar to that obtained after stimulation of these cells with methacholine (see b). Representative data from a single experiment from the experiments summarized in c solution alone (described in the "Materials and methods") or the pipette solution containing 20 μM of different polyphosphoinositides. As shown in Fig. 5 , following break-in, dialysis of cells with PIP 2 (Fig. 5a) or PIP (Fig. 5b) inhibited wortmannin-activated TRPC5 currents, while 20 μM of PIP 3 (Fig. 5c ) had no effect on TRPC5 currents. The inhibitory effects of polyphosphoinositides occurred after a delay of a minute or so, perhaps due to slow diffusion of the lipids through the patch pipette openings or in the cytoplasm.
Effects of PIP 2 on single TRPC5 channels
We next turned to measurement of the activity of TRPC5 channels in excised patches. This preparation should give rapid access to the intracellular surface of the plasma membrane and the channels in order to investigate their regulation. In excised patches, there was little apparent channel activity in control cells or in cells that had been pretreated with PI4-K inhibitors. Addition of PIP 2 to the patches resulted in robust activation of channels with a conductance at +60 mV of 64.6±0.1 pS (Fig. 6) , a value similar to that previously reported for TRPC5 [30] . The channels were also activated, albeit to a somewhat lesser extent by PIP 3 . Figure 7 summarizes a series of experiments showing that the channels were significantly activated by PIP 2 , but not by wortmannin, or by the de-acylated PIP 2 , glycerol-phosphoryl-inositol 4,5-bisphosphate (GPIP 2 ). The channels could also be activated by addition of ATP, possibly indicating that the phosphatidylinositol or PIP precursor and necessary kinases were present in the patches. In one series of experiments (Fig. 7c) in which there was measurable spontaneous activity in the patches, this activity was decreased by the PIP 2 scavenger, polylysine (PL).
Effect of membrane-targeted PIP 2 
5-phosphatase
The results to this point present a paradox: Pharmacological and whole-cell patch-clamp data suggest that PIP 2 exerts an inhibitory control on TRPC5, while the single-channel data suggest the PIP 2 activates the channels. We consider that the PI4-K inhibitors might affect different pools of PIP 2 than those involved in positive modulation of the channels. In addition, pharmacological inhibition of PI4-K not only decreases the levels of PIP 2 but also depletes, and likely to a greater extent, the levels of PI4P. Therefore, we sought to use a molecular tool to specifically deplete PIP 2 levels and assess its effect on TRPC5 activity. We adopted a strategy recently developed by Varnai et al. [35] whereby a cytoplasmic form of the PIP 2 5-phosphatase is targeted to the plasma membrane by rapamycin, as described in "Materials and methods". We confirmed that addition of rapamycin to agonist-activated wild-type cells resulted in (~50 s), data (outward at +100 mV, inward at −100 mV) were collected and normalized by ratio to the initial current density (I 0 ). The differences (control vs. lipid-treated) in inward and outward currents at the end of data collection were analyzed by t tests; the levels of significance were: PIP 2 , inward, P=0.059 (NS), outward, P=0.004; PIP, inward, P=0.049, outward, P=0.012; PIP 3 , inward, P=0.445 (NS), outward, P=0.519 (NS) rapid cessation of Ca 2+ signaling, as originally shown by Varnai et al. [35] ; addition of rapamycin to wild-type cells, or cells transfected with either of the two constructs alone, had no such effect (data not shown). Surprisingly, unlike the case for 4-kinase inhibitors, addition of rapamycin to TRPC5-expressing HEK293 cells did not activate TRPC5-mediated Ca 2+ entry, nor did rapamycin potentiate TRPC5 activation in response to low doses of agonist (5 μM; not shown). Rather, agonist-activated TRPC5-mediated Ca 2+ entry was strongly inhibited upon addition of rapamycin (Fig. 8) .
The 4-kinase inhibitors would decrease levels of both PIP and PIP 2 , while the targeted 5-phosphatase would decrease only PIP 2 , possibly increasing PIP. We thus considered the possibility that PIP might act to inhibit TRPC5, antagonizing the activation by PIP 2 . For these experiments, we determined the sensitivity of TRPC5 channels to PIP 2 ( Fig. 9a) and selected 1 μM PIP 2 as a submaximal concentration. Addition of a large excess of PIP (10 μM) to excised patches from TRPC5-expressing cells together with 1 μM PIP 2 caused no significant inhibition of TRPC5 channel activity (Fig. 9b,c) . PIP (10 μM), when applied alone, caused only modest activation of TRPC5 channel activity as compared to PIP 2 (Fig. 9c) . is specifically activated by PIP2 at the single-channel level. a Histograms summarizing changes observed in NPo at +60 mV during inside-out experiments where patches were exposed to a regular external solution (Cont.) and then to the same solution supplemented with 20 μM wortmannin alone (WT) or in the presence of 10 μM PIP 2 ; representative of four patches obtained in four independent cells. b Same as in a, but patches were exposed to 5 mM ATP alone (ATP) or in the presence of 10 μM PIP 2 (ATP + PIP 2 ); representative of four patches obtained in four independent cells. c Same as a and b, but patches were sequentially exposed to the regular external solution (Cont.), 10 μM GPIP 2 , 0.5 μg/ml poly-L-lysine (PL), and 10 μM PIP 2 ; representative of six patches obtained in six independent cells Fig. 6 PIP2 directly activates TRPC5 channels in the insideout configuration. a Representative traces showing TRPC5 activity at +60 mV immediately after excising a membrane patch from a cell exposed to wortmannin (top trace) and after a subsequent application of 10 μM PIP 2 (bottom trace). b Corresponding NPo vs. time plots for the same cell. Arrows indicate solution exchanges
Discussion
The mechanism of activation via PLC-coupled receptor stimulation of TRPC5 and TRPC4 has remained one of the unsolved mysteries in the TRPC field [57] . TRPC5 activation was shown to depend upon PLC, but clearly did not involve DAG or IP 3 [30] . Plant and Schaefer [57] reported that receptor-mediated activation of currents in cells transfected with TRPC4 and TRPC5 was unaffected by infusion of lowmolecular-weight heparin, ruling out the involvement of IP 3 receptors in TRPC5 activation. Venkatachalam et al. [27] showed that TRPC5 could be activated via a muscarinic receptor in DT40 B cells lacking all three IP 3 receptor subtypes. Strübing et al. [58] showed that like homomeric TRPC4 and TRPC5, heteromers formed between TRPC1 and TRPC5, were also not activated by infusion of IP 3 but responded to subsequent muscarinic receptor activation (but see [59] ). Otsuguro et al. [31] provided the first clues to the possible activation mechanism, demonstrating that TRPC4 activity was inhibited by polyphosphoinositides. Other findings in their study suggested that depletion of polyphosphoinositides played a role in activating TRPC4, but in conjunction with other signals such as G i /G o or a rise in [Ca 2+ ] i [31] .
In this study, we show that drugs that are expected to deplete polyphosphoinositides activate TRPC5 cation channels expressed in HEK293 cells, consistent with the Otsuguro et al. results, providing a possible mechanism of activation of TRPC5 channels through PLC-coupled receptor stimulation. We confirmed that the synthetic DAG, OAG was incapable of activating TRPC5 channels in our TRPC5-expressing HEK293 cell line. However, pharmacological inhibition of PI4-K by wortmannin and LY294002, which causes polyphosphoinositide depletion, was able to activate calcium entry and whole-cell TRPC5 current in TRPC5- Fig. 9 PIP weakly activates TRPC5 channels, but does not interfere with the ability of PIP2 to activate the channels. a Concentrationresponse curve showing the concentration-dependent effects of bath applied PIP 2 on TRPC5 channels. Single-channel events were recorded at 80 mV (10 μM: n=4; 1 μM: n=10; 500 nM: n=4; 100 nM: n=4). b Representative traces showing TRPC5 activity before, during, and after the simultaneous addition of 1 μM PIP 2 and 10 μM PIP to the cytosolic side of the membrane patch through the bathing solution. Arrow on top trace indicates where the 300 ms bottom trace was taken, showing TRPC5 activity under the presence of both PIP and PIP 2 . c Bar graph indicating the effects of 1 μM PIP 2 alone (n=10), 10 μM PIP alone (n=3), or PIP 2 plus PIP (n=7; added simultaneously as seen in b), as well as TRPC5 basal activity recorded before the addition of PIP or PIP2 (n=8). Error bars indicate means± SEM Fig. 8 PIP2 depletion using plasma membrane-targeted PI5 phosphatase inhibits TRPC5. Time course of average fluorescence ratio in TRPC5-expressing HEK293 cells loaded with Fura-2. Cells were exposed to a maximal dose of carbachol (CCh, 100 μM) in the presence of 2 mM external Ca 2+ solution and a low dose of Gd 3+ (5 μM) to block the endogenous store-operated Ca 2+ entry pathway, as indicated by the horizontal arrow bars. Once the TRPC5-mediated Ca 2+ entry fully developed, rapamycin (100 nM) was added where indicated. The trace shown represents average data of 21 cells from a recording representative of at least four separate experiments expressing HEK293 cells with no effect observed in wildtype HEK293 cells. We found no evidence for a role for cytoplasmic Ca 2+ signaling, since the muscarinic agonist as well as the 4-kinase inhibitors activated TRPC5 when cytoplasmic Ca 2+ was strongly buffered in the whole-cell configuration. Importantly, the 4-kinase inhibitors were unable to activate calcium entry and ionic currents in an HEK293 cell line stably expressing TRPC3 channels. Rather, muscarinic receptor activation of TRPC3 cation channels was completely abrogated by pretreatment with these drugs. Finally, activation of TRPC5 currents by wortmannin could be partially reversed by including PIP or PIP 2 , but not PIP 3 , in the patch pipette. We cannot relate the concentrations of these lipids in the patch pipette to physiological concentrations in the plasma membrane nor can we determine if either of these lipids can be interconverted to the other in this experimental situation. Thus, we cannot definitively determine which (or if both) of these lipids is the critical regulator of TRPC5. Nonetheless, these findings are consistent with the proposal that receptormediated activation of PLC activates TRPC5 through relief of inhibition by polyphosphoinositides.
It is well known that polyphosphoinositides are key regulators of many ion channels and transporters (for reviews, see [60] [61] [62] 18] ). In the majority of instances, this regulation is thought to be allosteric rather than a primary means of channel activation. In addition, in the majority of instances, polyphosphoinositides either activate or are required for activation of the channels. For most TRP superfamily members, polyphosphoinositides exert positive modulatory effects on channel activity [61, 63, 64] , and we have shown that this is the case for one member of the TRPC family, TRPC7 [65] . Surprisingly, we found that TRPC5 channels in excised patches showed low activity until PIP 2 was added to them. PIP was only a weak activator and did not appreciably affect the ability of PIP 2 to activate the channels. Furthermore, global depletion of PIP 2 by a membrane-targeted PIP 2 5-phosphatase strongly inhibited TRPC5 activity. This may mean that the 4-kinase inhibitors target a specific pool of PIP 2 or that components of the regulatory mechanism for TRPC5 channels is lost in the excised patch. Regardless, it seems clear that in addition to its role in the signaling pathway for TRPC5 activation, PIP 2 also plays a more fundamental positive role in TRPC5 function similar to that shown for the majority of TRP channels that have been studied. We propose a somewhat speculative model to accommodate these two apparently opposing effects of PIP 2 . We suggest that PIP 2 may be intimately associated with TRPC5 channels where it is needed for proper channel function. In addition, we propose an additional role for polyphosphoinositides (PIP 2 or PIP) in a signaling mechanism, perhaps involving a negative regulator that breaks TRPC5 in a polyphosphoinositidedependent manner. In an excised patch, this regulator may be gone, as well as the PIP 2 necessary for channel activity. Addition of PIP 2 in this circumstance would lead to channel activation. This model is summarized in Fig. 10 . Note that this model implies spatially restricted pools of polyphosphoinositides fulfilling these distinct functions; consistent with this idea, unlike its precursor, PIP, PIP 2 diffusion in the plasma membrane appears to be highly restricted due to interactions with the cytoskeleton [66] . In a recent study,
Intact Cell
Excised Patch Fig. 10 Model for PIP2 regulation of TRPC5 channels. In intact cells, agonist (Ag) activation of PLC, or inhibition of PI4-K by wortmannin, leads to reduction of PIP or PIP 2 and dissociation of a polyphosphoinositide-dependent inhibitor of TRPC5. PIP 2 associated with the channel is required for activity; thus, removal of the PIP 2 -dependent inhibitor leads to channel activation. In excised patches, both the PIP 2 required for channel activity as well as the inhibitor are lost; thus, addition of PIP 2 leads to robust channel activation Lukacs et al. [67] presented evidence that PIP 2 can dually regulate TRPV1 channels depending on the strength of the channel stimulus. In addition to activation by PLC-coupled receptor agonists, TRPC5 channels have been shown to be activated by store depletion [56] , by augmented membrane trafficking [68] , and can be activated in a direct manner by high concentrations of lanthanides [38] . Lanthanides are believed to bind to a specific site in the extracellular domain of the channel, leading to TRPC5 activation. However, because of the apparent complex roles of polyphosphoinositides, additional work will be needed to identify the exact site(s) on TRPC5 channels involved in phospholipid regulation. Members of the TRPC family of cation channels are increasingly recognized as important players in native calcium entry pathways controlling a wide variety of physiological functions in many cell types. Further work is needed to better understand the regulation of TRPC channels under physiological conditions and how this regulation participates in shaping complex physiological responses.
